echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The payment or nearly 1.4 billion US dollars, Merck authorized the Columbotai macromolecular tumor project to go overseas!

    The payment or nearly 1.4 billion US dollars, Merck authorized the Columbotai macromolecular tumor project to go overseas!

    • Last Update: 2022-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    (Health Times reporter Chen Linhui) On May 16, according to Sichuan Kelun Pharmaceutical, its holding subsidiary Sichuan Kelun Botai Biomedical .


    According to public information, Kelun Biotech is an innovative drug developer, focusing on the R&D, production and sales of innovative drug business, and its ADC drug (Antibody-drug Conjugate, antibody conjugated drug) pipeline has attracted much market attenti.


    This agreement is a licensing agreement for innovative dru.


    The staff of the Medicinal Chemistry Department of Sichuan Kelun Botai Biopharmaceutical .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.